Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma.

Literature DB >> 26388113

Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma.

Y Kato¹, A Otsuka², Y Miyachi¹, K Kabashima³.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2015 PMID： 26388113 DOI： 10.1111/jdv.13336

Source DB: PubMed Journal: J Eur Acad Dermatol Venereol ISSN： 0926-9959 Impact factor: 6.166

Keyword Cloud
Cited

× No keyword cloud information.

25 in total

Review 1. Autoimmunity and autoimmune co-morbidities in psoriasis.

Authors: Kazuhisa Furue; Takamichi Ito; Gaku Tsuji; Takafumi Kadono; Takeshi Nakahara; Masutaka Furue
Journal: Immunology Date: 2018-02-06 Impact factor: 7.397

Review 2. Cutaneous toxicities of new treatments for melanoma.

Authors: A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal: Clin Transl Oncol Date: 2018-05-24 Impact factor: 3.405

Review 3. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors: Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal: Curr Treat Options Oncol Date: 2020-03-19

4. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Authors: Genevieve J Kaunitz; Manisha Loss; Hira Rizvi; Sowmya Ravi; Jonathan D Cuda; Karen B Bleich; Jessica Esandrio; Inbal Sander; Dung T Le; Luis A Diaz; Julie R Brahmer; Charles G Drake; Travis J Hollmann; Mario E Lacouture; Matthew D Hellmann; Evan J Lipson; Janis M Taube
Journal: Am J Surg Pathol Date: 2017-10 Impact factor: 6.394

5. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.

Authors: Vasiliki Nikolaou; D Voudouri; G Tsironis; A Charpidou; G Stamoulis; I Triantafyllopoulou; I Panoutsopoulou; E Xidakis; A Bamias; E Samantas; G Aravantinos; H Gogas; D Rigopoulos; K Syrigos; A Stratigos
Journal: Support Care Cancer Date: 2019-03-27 Impact factor: 3.603

Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma.

Review 1. Autoimmunity and autoimmune co-morbidities in psoriasis.

Review 2. Cutaneous toxicities of new treatments for melanoma.

Review 3. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

4. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

5. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.

6. [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].

Review 7. Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors.

Review 8. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Review 9. Immune checkpoint inhibitor-related dermatologic adverse events.

10. A Case of De Novo Psoriasis Secondary to Nivolumab in a Patient With Metastatic Renal Cell Carcinoma.